Vera Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Vera Therapeutics, Inc. filed a Form 8-K reporting results of its 2024 Annual Meeting of Stockholders held on May 15, 2024. The company is a Delaware corporation whose Class A common stock trades on Nasdaq under the symbol VERA. The filing was signed on May 17, 2024.
Financial and Operating Metrics
This filing does not report revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics. As of the March 18, 2024 record date, 54,451,375 shares of Class A common stock were outstanding and entitled to vote.
Material Changes Versus the Prior Comparable Period
The filing does not provide a prior-period comparison or disclose financial or operating changes.
Meeting Results, Outlook, and Unusual Items
- Director elections: Stockholders elected Andrew Cheng, M.D., Ph.D., and Scott Morrison as Class III directors, each to serve until the 2027 Annual Meeting and until a successor is elected and qualified, subject to earlier death, resignation, or removal.
- Reported votes: Andrew Cheng received 27,436,839 votes for, 12,964,536 withheld, and 1,020,833 broker non-votes. Scott Morrison received 31,636,040 votes for, 8,765,335 withheld, and 1,020,833 broker non-votes.
- Accounting firm: Stockholders ratified the Audit Committee’s selection of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The vote was 41,413,260 for, 1,832 against, and 7,116 abstentions, with no broker non-votes.
- Data inconsistency: Proposal 1 states that three Class III directors were elected, but the provided filing text reports voting results for only two individuals. The filing text does not clearly identify the third director or provide its voting totals.
- No guidance, management outlook, risk update, contingency, financing transaction, or other unusual financial item is disclosed in the provided filing.
Key Facts for Investors to Verify
- Confirm the identity and voting results of the third Class III director referenced in Proposal 1.
- Confirm the elected directors’ biographies, committee assignments, and independence status in the company’s proxy materials.
- Review subsequent filings for any changes in board composition or auditor relationship.
- Use the company’s periodic financial filings, rather than this 8-K, to assess revenue, cash runway, liquidity, debt, operating expenses, and clinical or regulatory progress.